SARS
MCID: SVR001
MIFTS: 55

Severe Acute Respiratory Syndrome (SARS)

Categories: Blood diseases, Infectious diseases, Neuronal diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Severe Acute Respiratory Syndrome

MalaCards integrated aliases for Severe Acute Respiratory Syndrome:

Name: Severe Acute Respiratory Syndrome 12 74 52 3 43 15 17 71
Sars 12 52 3
Sars-Cov Infection 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2945
ICD9CM 34 079.82
MeSH 43 D045169
NCIt 49 C85064
ICD10 32 J12.81 U04 U04.9
UMLS 71 C1175175

Summaries for Severe Acute Respiratory Syndrome

CDC : 3 Severe acute respiratory syndrome (SARS) is a viral respiratory illness caused by a coronavirus called SARS-associated coronavirus (SARS-CoV). SARS was first reported in Asia in February 2003. The illness spread to more than two dozen countries in North America, South America, Europe, and Asia before the SARS global outbreak of 2003 was contained. Since 2004, there have not been any known cases of SARS reported anywhere in the world. The content in this website was developed for the 2003 SARS epidemic. But some guidelines are still being used. Any new SARS updates will be posted on this website.

MalaCards based summary : Severe Acute Respiratory Syndrome, also known as sars, is related to coronavirus infection and sarcoidosis 1, and has symptoms including fever, headache and dry cough. An important gene associated with Severe Acute Respiratory Syndrome is ACE2 (Angiotensin I Converting Enzyme 2), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Ziprasidone and Liraglutide have been mentioned in the context of this disorder. Affiliated tissues include respiratory tract, lung and testes, and related phenotype is immune system.

Disease Ontology : 12 A Coronavirus infection that results in infection located in respiratory tract, has material basis in SARS coronavirus (SARS-CoV), which is transmitted by droplet spread of respiratory secretions, transmitted by ingestion of contaminated food, or transmitted by fomites. The infection has symptom fever, has symptom headache, has symptom body aches, has symptom dry cough, and has symptom hypoxia.

Wikipedia : 74 Severe acute respiratory syndrome (SARS) is a viral respiratory disease of zoonotic origin caused by the... more...

Related Diseases for Severe Acute Respiratory Syndrome

Diseases in the Respiratory Failure family:

Severe Acute Respiratory Syndrome

Diseases related to Severe Acute Respiratory Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 696)
# Related Disease Score Top Affiliating Genes
1 coronavirus infection 32.7 TMPRSS2 MX1 MBL2 CLEC4M CCL2 ACE2
2 sarcoidosis 1 32.4 TNF CXCL10 CCL5 CCL2
3 respiratory failure 30.9 TNF IL6 IL10 CXCL8 CXCL10 CCL5
4 allergic encephalomyelitis 30.7 CCL5 CCL2
5 diarrhea 30.7 TNF IL6 IL10 IFNA1 CXCL8
6 adult respiratory distress syndrome 30.7 TNF IL6 IL10 CXCL8
7 bronchopneumonia 30.7 TNF IL6 IL10 CXCL8
8 hepatitis a 30.6 TNF IL10 IFNA1 CXCL10
9 pulmonary edema 30.6 TNF IL10 CXCL8
10 gastroenteritis 30.5 TNF IL6 IL10 IFNA1 CXCL8
11 venezuelan equine encephalitis 30.5 IFNB1 IFNA1 CXCL10 CCL2
12 bronchiectasis 30.5 TNF MBL2 IL6 CXCL8
13 vaccinia 30.5 TNF IRF3 IL6 IFNB1 IFNA1
14 bacterial pneumonia 30.4 TNF IL6 IL10 CXCL8
15 allergic contact dermatitis 30.4 TNF IL6 IL10 CXCL8 CCL2
16 hypereosinophilic syndrome 30.4 IL10 IFNA1 CXCL8 CCL5
17 chlamydia pneumonia 30.4 TNF IL6 IL10 CXCL8
18 bronchitis 30.4 TNF IL6 IL10 CXCL8 CXCL10 CCL5
19 common cold 30.4 TNF IL6 IL10 CXCL8 CCL5
20 bronchiolitis obliterans 30.4 TNF IL6 IL10 CXCL8
21 schistosomiasis 30.3 TNF IL10 CCL5 CCL2
22 avian influenza 30.3 TNF IL6 IFNA1 DDX58 CXCL8 CXCL10
23 rhinitis 30.3 TNF IL6 IL10 CXCL8 CCL5
24 west nile virus 30.3 IRF3 IFNA1 DDX58 CLEC4M CD209
25 sleeping sickness 30.3 IL6 IL10 CTSL
26 endophthalmitis 30.3 TNF IL6 CXCL8
27 contact dermatitis 30.3 TNF IL6 IL10 CXCL8 CXCL10 CCL2
28 haemophilus influenzae 30.3 TNF CXCL8
29 vasculitis 30.3 TNF MBL2 IL6 CCL2
30 visceral leishmaniasis 30.3 TNF IL10 CXCL8
31 endocarditis 30.2 TNF IL6 IL10 CXCL8
32 chagas disease 30.2 TNF IL6 IL10 CXCL8 CCL5 CCL2
33 streptococcal toxic-shock syndrome 30.2 TNF IL6 CXCL8
34 orchitis 30.2 TNF IL6 IL10
35 dengue disease 30.2 TNF MBL2 IFNB1 CLEC4M CD209 CCL5
36 toxic shock syndrome 30.2 TNF IL6 IL10 CXCL8
37 acquired immunodeficiency syndrome 30.2 TNF IL6 IL10 IFNA1
38 leishmaniasis 30.2 TNF MBL2 IL6 IL10 CXCL8 CCL2
39 mycoplasma pneumoniae pneumonia 30.2 TNF IL6 IL10
40 bronchiolitis 30.1 TNF IL6 IL10 CXCL8 CXCL10 CCL5
41 trypanosomiasis 30.1 TNF IL6 IL10 CXCL8 CXCL10 CCL5
42 lung disease 30.1 TNF MBL2 IL6 IL10 CXCL8 CXCL10
43 disseminated intravascular coagulation 30.1 TNF IL6 IL10
44 yellow fever 30.1 IL6 IFNB1 CXCL10 CCL5 CCL2
45 dermatitis 30.1 TNF IL6 IL10 CXCL8 CCL5
46 pneumonia 30.1 TNF MBL2 IL6 IL10 CXCL8 CXCL10
47 mycobacterium tuberculosis 1 30.1 TNF MBL2 IL10 IFNB1 CXCL10 CD209
48 chickenpox 30.1 TNF IL6 IL10
49 chlamydia 30.1 TNF MBL2 IL6 IL10 CXCL8 CCL2
50 echinococcosis 30.1 TNF IL6 IL10

Graphical network of the top 20 diseases related to Severe Acute Respiratory Syndrome:



Diseases related to Severe Acute Respiratory Syndrome

Symptoms & Phenotypes for Severe Acute Respiratory Syndrome

Symptoms:

12
  • fever
  • headache
  • dry cough
  • body aches
  • hypoxia

UMLS symptoms related to Severe Acute Respiratory Syndrome:


fever, pruritus, snoring, coughing

MGI Mouse Phenotypes related to Severe Acute Respiratory Syndrome:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.44 ACE2 CCL2 CCL5 CLEC4M CXCL10 DDX58

Drugs & Therapeutics for Severe Acute Respiratory Syndrome

Drugs for Severe Acute Respiratory Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 78)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ziprasidone Approved Phase 4 146939-27-7 60854
2
Liraglutide Approved Phase 4 204656-20-2 44147092
3
Glucagon Approved Phase 4 16941-32-5
4
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
5
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
6
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
7 Hypoglycemic Agents Phase 4
8 Quetiapine Fumarate Phase 4 111974-72-2
9 Incretins Phase 4
10 Hormone Antagonists Phase 4
11 Pharmaceutical Solutions Phase 4
12 Hormones Phase 4
13 Glucagon-Like Peptide 1 Phase 4
14 Tranquilizing Agents Phase 4
15 Neurotransmitter Agents Phase 4
16 Dopamine agonists Phase 4
17 Dopamine Antagonists Phase 4
18 Dopamine Agents Phase 4
19 Dopamine D2 Receptor Antagonists Phase 4
20 Serotonin 5-HT2 Receptor Antagonists Phase 4
21 Psychotropic Drugs Phase 4
22 Serotonin 5-HT1 Receptor Agonists Phase 4
23 Serotonin Agents Phase 4
24 Antipsychotic Agents Phase 4
25 Antidepressive Agents Phase 4
26 Central Nervous System Depressants Phase 4
27 Serotonin Receptor Agonists Phase 4
28 Serotonin Antagonists Phase 4
29
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
30
Heparin Approved, Investigational Phase 3 9005-49-6 772 46507594
31
Streptokinase Approved, Investigational Phase 3 9002-01-1
32
Calcium Approved, Nutraceutical Phase 3 7440-70-2 271
33 Fibrinolytic Agents Phase 3
34 Anticoagulants Phase 3
35 Calcium, Dietary Phase 3
36 calcium heparin Phase 3
37
Interferon alfacon-1 Approved, Investigational Phase 1, Phase 2 118390-30-0 9554198
38 interferons Phase 2
39 Rho(D) Immune Globulin Phase 2
40 Immunoglobulins, Intravenous Phase 2
41 gamma-Globulins Phase 2
42 Antibodies Phase 2
43 Immunoglobulins Phase 2
44 Interferon-alpha Phase 2
45 Immunoglobulin G Phase 2
46 Anti-Infective Agents Phase 2
47 Antiviral Agents Phase 2
48 Antimetabolites Phase 2
49 Immunologic Factors Phase 2
50 Vaccines Phase 2

Interventional clinical trials:

(show top 50) (show all 52)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of Lectranal® in Treatment of Seasonal Allergic Rhinitis Symptoms Completed NCT00460538 Phase 4
2 Phase IV Study of Effectiveness of Aripiprazole, Quetiapine, and Ziprasidone in the Treatment of First Episode of Non-affective Psychosis Individuals Included in the First Episode Psychosis Clinical Program II (PAFIP II): a 3-year Follow-up Completed NCT02526030 Phase 4 Aripiprazole;Quetiapine;Ziprasidone
3 Phase IV Study of the Effectiveness of Aripiprazole, Quetiapine, and Ziprasidone in the Treatment of First Episode of Non-affective Psychosis Individuals Included in the First Episode Psychosis Clinical Program II (PAFIP II) Completed NCT02305823 Phase 4 Aripiprazole;Quetiapine;Ziprasidone
4 Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: a Randomized Comparison of Aripiprazole, Quetiapine and Ziprasidone Over 1 Year Completed NCT02534363 Phase 4 Aripiprazole;Quetiapine;Ziprasidone
5 Magnetic Resonance Assessment of Victoza Efficacy in the Regression of Cardiovascular Dysfunction In Type 2 Diabetes Mellitus and South Asian Descent Completed NCT02660047 Phase 4 Liraglutide;Liraglutide - Placebo
6 Magnetic Resonance Assessment of Victoza Efficacy in the Regression of Cardiovascular Dysfunction In Type 2 Diabetes Mellitus Completed NCT01761318 Phase 4 Liraglutide;Liraglutide - Placebo
7 Open Flexible-dose Randomized Study of the Effectiveness of Second Generation Antipsychotics in First Episode Psychosis Patients: A 3-year Follow-up Enrolling by invitation NCT03090503 Phase 4 Aripiprazole;Risperidone
8 Open Flexible-dose Randomized Study of the Effectiveness of Second Generation Antipsychotics in First Episode Psychosis Patients: A 1-year Follow-up Enrolling by invitation NCT02532491 Phase 4 Aripiprazole;Risperidone
9 Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: a Randomized Comparison of Aripiprazole and Risperidone Over 3 Years Enrolling by invitation NCT03883204 Phase 4 Aripiprazole;Risperidone
10 Streptokinase Versus Unfractionated Heparin Nebulization in Patients With Severe Acute Respiratory Distress Syndrome (ARDS): A Partially Randomized Controlled Trial Completed NCT03465085 Phase 3 Unfractionated heparin;Streptokinase
11 Emergency Evaluation of Convalescent Plasma for Ebola Viral Disease (EVD) in Guinea Completed NCT02342171 Phase 2, Phase 3
12 A Pilot Study to Evaluate the Safety and Efficacy of IFN-alfacon1 (INFERGEN) in the Treatment of Hospitalized Patients Presenting With Influenza-like Illnesses Due to the Pandemic 2009 Swine Origin Influenza A Virus (S-OIV) H1N1 and Other Circulating Influenza Viruses Unknown status NCT01227798 Phase 1, Phase 2 Interferon alfacon-1;Placebo
13 A Randomized, Dose-ranging Study of Alferon® LDO {Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)} in Normal Volunteers and/or Asymptomatic Subjects With Exposure to a Person Known to Have SARS or Possible SARS Completed NCT00215826 Phase 2 Alferon LDO
14 Immunoglobulin for Necrotizing Soft Tissue Infections: a Randomised Controlled Trial Completed NCT02111161 Phase 2 IVIG (Privigen);Saline 0.9%
15 Using Systems Vaccinology to Elucidate the Effects of Anti-inflammatory Therapy on Immune Response After Vaccination With a Live Attenuated Vaccine Recruiting NCT03116802 Phase 2 Stamaril (live attenuated yellow fever vaccine)
16 A Randomised, Double-blind, Placebo-controlled Trial to Evaluate the Effect of Epstein-Barr Virus Suppression in Chronic Obstructive Pulmonary Disease (EViSCO). Recruiting NCT03699904 Phase 2 Valaciclovir;Placebo capsules (containing Avicel blend)
17 Anti-MERS-COV Convalescent Plasma Therapy Withdrawn NCT02190799 Phase 2
18 Phase I, Open-label, Dose Ranging Study to Evaluate the Safety, Tolerability, and Immunogenicity of GLS-5300, Administered IM Followed by Electroporation in Healthy Volunteers Completed NCT02670187 Phase 1
19 A Phase I Study of the Safety and Immunogenicity of a SARS Recombinant DNA Plasmid Vaccine, VRC-SRSDNA015-00-VP, in Healthy Adult Volunteers Completed NCT00099463 Phase 1 Vaccine;VRC-SRSDNA015-00-VP
20 A Phase I Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Co-administered MERS-CoV Antibodies REGN3048 and REGN3051 vs. Placebo in Healthy Adults Completed NCT03301090 Phase 1
21 A Phase I Double-Blind, Placebo-Controlled, Dose-Escalating Study to Evaluate the Safety and Tolerability of Topical Nasal Poly-ICLC Completed NCT00646152 Phase 1 Poly-ICLC
22 A First-in-Human Safety and Dose-Finding Study of New Type-16 Human Rhinovirus (RG-HRV16) Inoculum in Healthy Volunteers Completed NCT01769573 Phase 1 Placebo
23 Phase I, Double-Blinded, Placebo-Controlled, Dose- Escalation Study of the Safety and Immunogenicity of Recombinant SARS-CoV deltaTM S Protein Vaccine Formulated With and Without Alhydrogel® in Healthy Adults When Administered by the Intramuscular Route Withdrawn NCT01376765 Phase 1 Aluminum hydroxide adjuvant (Alhydrogel®)
24 Phase I, Double-Blinded, Placebo-Controlled Dosage Escalation Study of the Safety and Immunogenicity of Adjuvanted and Non-Adjuvanted Inactivated SARS Coronavirus (SARS-CoV) Vaccine Administered by the Intramuscular Route Withdrawn NCT00533741 Phase 1 Aluminum hydroxide;Placebo
25 A Multi-centre, Double-blinded, Randomized, Placebo-controlled Trial on the Efficacy and Safety of Lopinavir / Ritonavir Plus Ribavirin in the Treatment of Severe Acute Respiratory Syndrome Unknown status NCT00578825 Lopinavir / Ritonavir plus Ribavirin
26 Induction of Cytokines in Human Monocytes by SARS-CoV in Adults and Children Unknown status NCT00173563
27 Clinical Study of SARS in Children Completed NCT00173576
28 An Investigation of the Inflammatory Response in Severe Acute Respiratory Syndrome (SARS) Completed NCT00066209
29 Dynamic Profiles of Cytokine/Chemokine in Severe Acute Respiratory Syndrome Completed NCT00173459
30 Collection of Convalescent SARS Plasma by Apheresis Completed NCT00342524
31 The Physiological Impact of N95 Masks on Medical Staff Completed NCT00173017
32 Contamination During Removal of Two Different Personal Protective Systems When Working Under Conditions Requiring Enhanced Respiratory and Contact Precautions Completed NCT00150475
33 Testing of Respiratory Specimens for the Validation of the QIAGEN ResPlex II Advanced Panel Test and the Artus Influenza A/B RT-PCR Test Completed NCT01302418
34 Seoul St. Mary's Hospital College of Medicine The Catholic University of Korea, Seoul, Korea Completed NCT01058733
35 Seroprevalence of IgG Antibodies to Middle East Respiratory Syndrome Coronavirus in Asymptomatic Healthcare Workers After Treatment of Confirmed MERS Patient Completed NCT02497885
36 A Multicentre, Open Label, Nonrandomised, Non-interventional, Observational, Safety Study in Subjects Using Insulin Detemir for the Treatment of Insulin Dependent Type 1 or Type 2 Diabetes Mellitus: The PREDICTIVE™ Study: Predictable Results and Experience in Diabetes Through Intensification and Control to Target: an International Variability Evaluation Completed NCT00659295 insulin detemir
37 VRC 300: Screening of Healthy Volunteers for Clinical Trials of Investigational Vaccines to Prevent Infectious Diseases Completed NCT00068926
38 A Multi-centre, International 14-day Inception Cohort Study of Severe Acute Respiratory Infections on the Intensive Care Unit Completed NCT01936207
39 An International Observational Study to Characterize Adults With Influenza or Other Targeted Respiratory Viruses Completed NCT01056354
40 SafeBoosC - Safeguarding the Brain of Our Smallest Children - an Investigator-initiated Randomised, Blinded, Multinational, Phase II Feasibility Clinical Trial on Near-infrared Spectroscopy Monitoring Combined With Defined Treatment Guidelines Versus Standard Monitoring and Treatment as Usual in Premature Infants Completed NCT01590316
41 The 15-year Impact of Severe Acute Respiratory Syndrome on Organ Functions, Exercise Capacity, and Quality of Life in Survivors. Recruiting NCT03443102
42 Admission and Management of Occupational or Other Exposures to Biodefense/Bioterrorism Agents or to Epidemic/Emerging Infectious Diseases Recruiting NCT01200953
43 A Prospective Study to Detect Novel Pathogens and Characterize Emerging Infections Recruiting NCT01979705
44 An International Observational Study to Characterize Adults Who Are Hospitalized With Influenza or Other Targeted Respiratory Viruses Recruiting NCT01056185
45 The Effectiveness of an Empirical Chinese Medicine Formulation for Idiopathic Pulmonary Fibrosis: an Open Label Clinical Trial Recruiting NCT03274544
46 Implementation of Lung Protective Ventilation in Patients With Acute Respiratory Failure Recruiting NCT03225807
47 A Clinical Cohort Study of Pneumonia in Respiratory Intensive Care Unit Recruiting NCT02738645
48 The Threat of Infectious Encephalitis in Southeast Asia: SouthEast Asia Encephalitis Project Active, not recruiting NCT04089436
49 Collection of Plasma From Subjects That Recovered From or Were Vaccinated To Emerging Infectious Diseases Enrolling by invitation NCT02338986
50 The Interaction Between Severe Acute Respiratory Distress Syndrome Viral Proteins and Monocytes Withdrawn NCT00172263

Search NIH Clinical Center for Severe Acute Respiratory Syndrome

Cochrane evidence based reviews: severe acute respiratory syndrome

Genetic Tests for Severe Acute Respiratory Syndrome

Anatomical Context for Severe Acute Respiratory Syndrome

The Foundational Model of Anatomy Ontology organs/tissues related to Severe Acute Respiratory Syndrome:

19
Respiratory Tract

MalaCards organs/tissues related to Severe Acute Respiratory Syndrome:

40
Lung, Testes, T Cells, Bone, Brain, Skin, Liver

Publications for Severe Acute Respiratory Syndrome

Articles related to Severe Acute Respiratory Syndrome:

(show top 50) (show all 8891)
# Title Authors PMID Year
1
Inhibition of SARS-CoV 3CL protease by flavonoids. 61
31724441 2020
2
Emergency nurses' perceptions regarding the risks appraisal of the threat of the emerging infectious disease situation in emergency departments. 61
31975652 2020
3
Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. 61
31987001 2020
4
Seryl-tRNA synthetase is involved in methionine stimulation of β-casein synthesis in bovine mammary epithelial cells. 61
31711551 2020
5
A pneumonia outbreak associated with a new coronavirus of probable bat origin. 61
32015507 2020
6
Persistence of coronaviruses on inanimate surfaces and its inactivation with biocidal agents. 61
32035997 2020
7
Emerging novel Coronavirus (2019-nCoV) - Current scenario, evolutionary perspective based on genome analysis and recent developments. 61
32036774 2020
8
Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China. 61
32035028 2020
9
Estimating the Unreported Number of Novel Coronavirus (2019-nCoV) Cases in China in the First Half of January 2020: A Data-Driven Modelling Analysis of the Early Outbreak. 61
32024089 2020
10
Pathogenicity and Transmissibility of 2019-nCoV-A Quick Overview and Comparison with Other Emerging Viruses. 61
32032682 2020
11
[Potential antiviral therapeutics for 2019 Novel Coronavirus]. 61
32023685 2020
12
Griffithsin Inhibits Nipah Virus Entry and Fusion and Can Protect Syrian Golden Hamsters From Lethal Nipah Virus Challenge. 61
32037447 2020
13
Identification of 6'-β-fluoro-homoaristeromycin as a potent inhibitor of chikungunya virus replication. 61
31841728 2020
14
SARS to novel coronavirus - old lessons and new lessons. 61
32019614 2020
15
Emerging threats from zoonotic coronaviruses-from SARS and MERS to 2019-nCoV. 61
32035811 2020
16
Evaluation of an octahydroisochromene scaffold used as a novel SARS 3CL protease inhibitor. 61
31926775 2020
17
Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV. 61
32022370 2020
18
[2019-nCoV: new challenges from coronavirus]. 61
32023682 2020
19
The Novel Coronavirus: A Bird's Eye View. 61
32020915 2020
20
Ethics of socially assistive robots in aged-care settings: a socio-historical contextualisation. 61
31818967 2020
21
A new coronavirus associated with human respiratory disease in China. 61
32015508 2020
22
The first two cases of 2019-nCoV in Italy: where they come from? 61
32022275 2020
23
Effects of a Humanoid Socially Assistive Robot Versus Tablet Training on Psychosocial and Physical Outcomes of Persons With Dementia: Protocol for a Mixed Methods Study. 61
32022697 2020
24
Design, synthesis, and biochemical characterization of non-native antagonists of the Pseudomonas aeruginosa quorum sensing receptor LasR with nanomolar IC50 values. 61
32037806 2020
25
Proton pump inhibitors selectively suppress MLL rearranged leukemia cells via disrupting MLL1-WDR5 protein-protein interaction. 61
31923859 2020
26
Artemisinin-derived dimers as potential anticancer agents: Current developments, action mechanisms, and structure-activity relationships. 61
31797422 2020
27
Semisynthesis and biological evaluation of amidochelocardin derivatives as broad-spectrum antibiotics. 61
31911294 2020
28
Discovery of novel 1,2,3-triazole oseltamivir derivatives as potent influenza neuraminidase inhibitors targeting the 430-cavity. 61
31835169 2020
29
The discovery of novel indazole derivatives as tubulin colchicine site binding agents that displayed potent antitumor activity both in vitro and in vivo. 61
31865012 2020
30
Parasite prevalence in intermediate hosts increases with waterbody age and abundance of final hosts. 61
32006182 2020
31
Synchronized Biventricular Heart Pacing in a Closed-chest Porcine Model based on Wirelessly Powered Leadless Pacemakers. 61
32034237 2020
32
Optimization and evaluation of novel tetrahydropyrido[4,3-d]pyrimidine derivatives as ATX inhibitors for cardiac and hepatic fibrosis. 61
31806537 2020
33
Genomic variance of the 2019-nCoV coronavirus. 61
32027036 2020
34
Inactivation of three emerging viruses - severe acute respiratory syndrome coronavirus, Crimean-Congo haemorrhagic fever virus and Nipah virus - in platelet concentrates by ultraviolet C light and in plasma by methylene blue plus visible light. 61
31930543 2020
35
Recent discovery and development of inhibitors targeting coronaviruses. 61
32006468 2020
36
A systematic risk-based strategy to select personal protective equipment for infectious diseases. 61
31358421 2020
37
The 2019-new coronavirus epidemic: Evidence for virus evolution. 61
31994738 2020
38
An integrative review of the limited evidence on international travel bans as an emerging infectious disease disaster control measure. 61
32031668 2020
39
Deducing the Crystal Structure of MERS-CoV Helicase. 61
31883088 2020
40
Discovery of Bat Coronaviruses through Surveillance and Probe Capture-Based Next-Generation Sequencing. 61
31996413 2020
41
Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study. 61
32004165 2020
42
Middle East Respiratory Syndrome Coronavirus Antibodies in Bactrian and Hybrid Camels from Dubai. 61
31969478 2020
43
Nucleocapsid Protein Recruitment to Replication-Transcription Complexes Plays a Crucial Role in Coronaviral Life Cycle. 61
31776274 2020
44
What Should Health Science Journalists Do in Epidemic Responses? 61
31958392 2020
45
Thiazinoquinones as New Promising Multistage Schistosomicidal Compounds Impacting Schistosoma mansoni and Egg Viability. 61
31718145 2020
46
Protein-Ligand Complex Solvation Thermodynamics: Development, Parameterization, and Testing of GIST-Based Solvent Functionals. 61
31922753 2020
47
Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. 61
31992387 2020
48
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. 61
31986264 2020
49
Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. 61
32007145 2020
50
Pattern of early human-to-human transmission of Wuhan 2019 novel coronavirus (2019-nCoV), December 2019 to January 2020. 61
32019669 2020

Variations for Severe Acute Respiratory Syndrome

Expression for Severe Acute Respiratory Syndrome

Search GEO for disease gene expression data for Severe Acute Respiratory Syndrome.

Pathways for Severe Acute Respiratory Syndrome

Pathways related to Severe Acute Respiratory Syndrome according to GeneCards Suite gene sharing:

(show top 50) (show all 54)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.07 TNF MX1 MBL2 IRF3 IL6 IL10
2
Show member pathways
13.7 TNF IL6 IL10 IFNB1 IFNA1 CXCL8
3
Show member pathways
13.55 TNF IL6 IL10 IFNB1 IFNA1 CXCL8
4
Show member pathways
13.32 TNF IL6 IL10 CXCL8 CXCL10 CCL5
5
Show member pathways
13.29 TNF MX1 IRF3 IL6 IL10 IFNB1
6
Show member pathways
13.01 TNF MX1 IRF3 IL6 IFNB1 IFNA1
7
Show member pathways
13.01 TNF IRF3 IL6 IFNB1 IFNA1 CXCL8
8
Show member pathways
12.89 TNF IL6 IL10 IFNA1 CXCL8 CTSL
9 12.86 TNF IRF3 IL6 IFNB1 IFNA1 DDX58
10
Show member pathways
12.75 TNF IRF3 IL6 IFNB1 IFNA1 DDX58
11
Show member pathways
12.7 TNF MX1 MBL2 IRF3 IL6 IL10
12 12.59 TNF IRF3 IL10 IFNA1 DDX58 CXCL10
13
Show member pathways
12.57 MX1 IRF3 IFNB1 IFNA1 DDX58
14 12.43 TNF IRF3 IFNB1 CXCL8 CCL5
15
Show member pathways
12.4 TNF IL6 IL10 CXCL8 CXCL10 CCL5
16
Show member pathways
12.38 TNF IL6 CXCL8 CXCL10 CCL2
17
Show member pathways
12.36 IL6 IL10 IFNB1 IFNA1
18
Show member pathways
12.35 TNF IL6 CCL5 CCL2
19
Show member pathways
12.32 TNF IRF3 IL6 IFNB1 CXCL8
20
Show member pathways
12.32 TNF MX1 IRF3 IL6 IL10 IFNB1
21
Show member pathways
12.31 TNF IRF3 IL6 CXCL8
22
Show member pathways
12.27 TNF IL6 IL10 CLEC4M CD209
23
Show member pathways
12.27 TNF IL6 IFNB1 CXCL8 CXCL10 CTSL
24 12.26 TNF IL6 IL10 IFNB1 IFNA1 CLEC4M
25 12.21 TNF IL6 IL10 CXCL8
26 12.18 MBL2 CTSL CLEC4M CD209
27
Show member pathways
12.18 TNF TMPRSS2 MX1 IRF3 IL6 IFNB1
28 12.12 TNF IRF3 IL6 IFNB1 IFNA1 CXCL8
29 12.1 TNF IL6 CXCL8 CXCL10 CCL2
30 12.08 TNF IL6 IL10 CXCL8 CCL2
31 12.06 TNF IL6 IFNB1 CXCL10 CCL5 CCL2
32 12.04 TNF IL6 IL10 CD209
33 11.98 TNF IL6 IL10 CXCL8
34 11.96 TNF IL6 CXCL8 CCL2
35 11.94 TNF IL6 CXCL8 CTSL CCL5 CCL2
36 11.94 TNF IRF3 IL6 IL10 IFNB1 CXCL8
37 11.93 IL6 IL10 IFNB1 IFNA1
38 11.87 TNF IRF3 IL6 IL10 CXCL8
39 11.85 TNF IL6 IL10 IFNB1 CD209
40 11.76 TNF IL6 CXCL8 CCL5 CCL2
41 11.7 TNF IL6 IL10 CXCL10 CCL5 CCL2
42
Show member pathways
11.68 TNF IL6 CXCL8
43 11.64 TNF IL6 IL10 CXCL8 CCL2
44 11.63 TNF IL6 CXCL8
45 11.5 IL6 IFNB1 IFNA1
46 11.43 TNF IL6 IL10
47 11.4 TNF IL6 IL10
48 11.39 TNF IL6 IL10 CXCL8 CXCL10 CCL5
49 11.38 IL6 CXCL8 CCL2
50 11.37 TNF IL6 IL10 IFNB1

GO Terms for Severe Acute Respiratory Syndrome

Cellular components related to Severe Acute Respiratory Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.77 TNF MBL2 IL6 IL10 IFNB1 IFNA1
2 extracellular region GO:0005576 9.5 TNF TMPRSS2 MBL2 IL6 IL10 IFNB1

Biological processes related to Severe Acute Respiratory Syndrome according to GeneCards Suite gene sharing:

(show top 50) (show all 57)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.23 TNF IRF3 IL6 IL10 IFNB1 DDX58
2 immune system process GO:0002376 10.14 MX1 MBL2 IRF3 DDX58 CLEC4M CD209
3 innate immune response GO:0045087 10.11 MX1 MBL2 IRF3 DDX58 CLEC4M CD209
4 viral process GO:0016032 10.1 IRF3 DDX58 CLEC4M CD209 ACE2
5 immune response GO:0006955 10.07 TNF IL6 IL10 CXCL8 CXCL10 CCL5
6 adaptive immune response GO:0002250 10.05 IFNB1 IFNA1 CTSL CLEC4M CD209
7 inflammatory response GO:0006954 10 TNF IL6 IL10 CXCL8 CXCL10 CCL5
8 chemotaxis GO:0006935 9.96 CXCL8 CXCL10 CCL5 CCL2
9 positive regulation of DNA-binding transcription factor activity GO:0051091 9.91 TNF IL6 IL10 DDX58
10 viral entry into host cell GO:0046718 9.9 CLEC4M CD209 ACE2
11 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.9 TNF SH2D3A IL6
12 cellular response to interleukin-1 GO:0071347 9.88 CXCL8 CCL5 CCL2
13 regulation of inflammatory response GO:0050727 9.88 TNF IRF3 ACE2
14 B cell differentiation GO:0030183 9.88 IL10 IFNB1 IFNA1
15 neutrophil chemotaxis GO:0030593 9.88 CXCL8 CXCL10 CCL5 CCL2
16 defense response GO:0006952 9.88 TNF MX1 IFNB1 IFNA1 CXCL8 CXCL10
17 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.87 TNF IL6 CCL5
18 cellular response to organic cyclic compound GO:0071407 9.87 TNF CCL5 CCL2
19 response to glucocorticoid GO:0051384 9.87 TNF IL6 IL10
20 positive regulation of T cell proliferation GO:0042102 9.86 IL6 CD209 CCL5
21 chemokine-mediated signaling pathway GO:0070098 9.86 CXCL8 CXCL10 CCL5 CCL2
22 positive regulation of interleukin-6 production GO:0032755 9.85 TNF IL6 DDX58
23 positive regulation of smooth muscle cell proliferation GO:0048661 9.85 TNF IL6 CCL5
24 type I interferon signaling pathway GO:0060337 9.85 MX1 IRF3 IFNB1 IFNA1
25 monocyte chemotaxis GO:0002548 9.82 IL6 CCL5 CCL2
26 antigen processing and presentation GO:0019882 9.82 CTSL CLEC4M CD209
27 protein kinase B signaling GO:0043491 9.81 TNF CCL5 CCL2
28 negative regulation of viral genome replication GO:0045071 9.81 TNF MX1 IFNB1 CCL5
29 B cell proliferation GO:0042100 9.8 IL10 IFNB1 IFNA1
30 response to exogenous dsRNA GO:0043330 9.8 IRF3 IFNB1 IFNA1 DDX58
31 cellular response to fibroblast growth factor stimulus GO:0044344 9.79 CXCL8 CCL5 CCL2
32 positive regulation of cytokine secretion GO:0050715 9.78 TNF IRF3 IL10
33 lipopolysaccharide-mediated signaling pathway GO:0031663 9.78 TNF IRF3 CCL5 CCL2
34 leukocyte cell-cell adhesion GO:0007159 9.77 CLEC4M CD209 CCL5
35 leukocyte chemotaxis GO:0030595 9.76 IL10 CXCL8 CXCL10
36 cellular response to exogenous dsRNA GO:0071360 9.74 IRF3 IFNB1 DDX58
37 positive regulation of JAK-STAT cascade GO:0046427 9.73 TNF IL6 IL10 CCL5
38 response to virus GO:0009615 9.73 TNF MX1 IFNB1 DDX58 CXCL10 CCL5
39 positive regulation of neuroinflammatory response GO:0150078 9.72 TNF IL6
40 neutrophil activation GO:0042119 9.72 CXCL8 CCL5
41 humoral immune response GO:0006959 9.72 TNF IL6 IFNB1 IFNA1 CCL2
42 PERK-mediated unfolded protein response GO:0036499 9.71 CXCL8 CCL2
43 positive regulation of interferon-alpha production GO:0032727 9.71 IRF3 DDX58
44 response to molecule of bacterial origin GO:0002237 9.71 IL10 CXCL8
45 viral genome replication GO:0019079 9.71 CLEC4M CD209 CCL2
46 negative regulation of lipid storage GO:0010888 9.7 TNF IL6
47 defense response to virus GO:0051607 9.7 MX1 IRF3 IL6 IFNB1 IFNA1 DDX58
48 endothelial cell apoptotic process GO:0072577 9.69 TNF IL10
49 modulation by virus of host morphology or physiology GO:0019048 9.67 CLEC4M CD209
50 cell-cell recognition GO:0009988 9.67 CLEC4M CD209

Molecular functions related to Severe Acute Respiratory Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 virus receptor activity GO:0001618 9.43 CLEC4M CD209 ACE2
2 mannose binding GO:0005537 9.33 MBL2 CLEC4M CD209
3 virion binding GO:0046790 9.32 CLEC4M CD209
4 cytokine activity GO:0005125 9.28 TNF IL6 IL10 IFNB1 IFNA1 CXCL8
5 chemokine activity GO:0008009 9.26 CXCL8 CXCL10 CCL5 CCL2

Sources for Severe Acute Respiratory Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....